Views

CrossRef citations to date

Altmetric

Articles

Ten-Year Retention Rate of Infliximab in Patients with Behçet’s Disease-Related Uveitis

Claudia FabianiDepartment of Ophthalmology, Humanitas Clinical and Research Center, Rozzano (Milan), Italy

, MD, PhD,

Jurgen SotaResearch Center of Systemic Autoinflammatory Diseases and Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy

, MD,

Antonio VitaleResearch Center of Systemic Autoinflammatory Diseases and Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy

, MD,

Giacomo EmmiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy

, MD, PhD,

Lorenzo VannozziDepartment of Surgery and Translational Medicine, Eye Clinic, University of Florence, Florence, Italy.

, MD,

Daniela BacheriniDepartment of Surgery and Translational Medicine, Eye Clinic, University of Florence, Florence, Italy.

, MD, PhD,

Giuseppe LopalcoInterdisciplinary Department of Medicine, Rheumatology Unit, University of Bari, Bari, Italy

, MD,

Silvana GuerrieroDepartment of Ophthalmology and Otolaryngology, University of Bari, Bari, Italy

, MD,

Vincenzo VeneritoInterdisciplinary Department of Medicine, Rheumatology Unit, University of Bari, Bari, Italy

, MD,

Ida OrlandoResearch Center of Systemic Autoinflammatory Diseases and Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy

, MD,

Rossella FranceschiniOphthalmology and Neurosurgery Department, University of Siena, Siena, Italy

, MD,

Fiorella FuscoOphthalmology and Neurosurgery Department, University of Siena, Siena, Italy

, MD,

Bruno FredianiResearch Center of Systemic Autoinflammatory Diseases and Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy

, MD,

Mauro GaleazziResearch Center of Systemic Autoinflammatory Diseases and Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy

, MD,

Florenzo IannoneInterdisciplinary Department of Medicine, Rheumatology Unit, University of Bari, Bari, Italy

, MD,

Gian Marco TosiOphthalmology and Neurosurgery Department, University of Siena, Siena, Italy

, MD, PhD &

Luca CantariniResearch Center of Systemic Autoinflammatory Diseases and Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, ItalyCorrespondence[email protected] [email protected]

http://orcid.org/0000-0002-7352-1275

, MD, PhD

show all

ABSTRACT

Purpose: To evaluate the 10-year drug retention rate of infliximab (IFX) in Behçet’s disease (BD)-related uveitis, the effect of a concomitant use of disease modifying anti-rheumatic drugs (DMARDs) on drug survival and differences according to the lines of biologic treatment.

Methods: Cumulative survival rates were studied using the Kaplan-Meier plot, while the Log-rank (Mantel-Cox) test was used to compare survival curves.

Results: Forty patients (70 eyes) were eligible for analysis. The drug retention rates at 12-, 24-, 60- and 120-month follow-up were 89.03%, 86.16%, 75.66% and 47.11% respectively. No differences were identified according to the use of concomitant DMARDs (p = 0.20), while a statistically significant difference was observed in relation to the different lines of IFX treatment (p = 0.014). Visual acuity improved from baseline to the last follow-up visit (p = 0.047) and a corticosteroid-sparing effect was observed (p < 0.0001).

Conclusions: IFX retention rate in BD-uveitis is excellent and is not affected by concomitant DMARDs.

Keywords:

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Ten-Year Retention Rate of Infliximab in Patients with Behçet’s Disease-Related Uveitis

Related Research Data

Information for

Open access

Opportunities

Help and information

Ten-Year Retention Rate of Infliximab in Patients with Behçet’s Disease-Related Uveitis

ABSTRACT

Declaration of interest

Reprints and Corporate Permissions

Academic Permissions

Related Research Data

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature